Research programme: bispecific iNKT cell engagers - MiNK Therapeutics
Latest Information Update: 31 May 2023
At a glance
- Originator MiNK Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer T cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 31 Dec 2022 Preclinical trials in Solid tumours in USA (Parenteral) prior to December 2022 (MiNK Therapeutics pipeline, May 2023)